| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.068 | 0.2 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | 0.067 | 0.2 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | -0.073 | 0.2 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.2 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.046 | 0.2 |